ID   SP-49
AC   CVCL_D022
SY   Sp-49; SP49
DR   cancercelllines; CVCL_D022
DR   Cosmic; 1070709
DR   Cosmic; 2296991
DR   GEO; GSM115806
DR   GEO; GSM1266773
DR   GEO; GSM1266774
DR   Progenetix; CVCL_D022
DR   Wikidata; Q54955386
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3121553;
RX   PubMed=9738977;
RX   PubMed=16960149;
RX   PubMed=19358282;
RX   PubMed=24362935;
RX   PubMed=25960936;
CC   Population: Japanese.
CC   Doubling time: 60 hours (PubMed=3121553).
CC   HLA typing: A*02:06,24:02; B*56:01,40:02; C*04:01,03:04; DQA1*03:02,03:02; DQB1*03:02,03:02; DRB1*04:05,08:02 (PubMed=25960936).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C121 ! SP-50B
OI   CVCL_M655 ! SP-52EB
OI   CVCL_C122 ! SP-53
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 17
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=3121553; DOI=10.20772/cancersci1985.78.11_1182;
RA   Daibata M., Takasaki M., Hirose S., Kubonishi I., Taguchi H.,
RA   Ohtsuki Y., Miyoshi I.;
RT   "Establishment of a new human B cell line carrying t(11;14) chromosome
RT   abnormality.";
RL   Jpn. J. Cancer Res. 78:1182-1185(1987).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x; PMCID=PMC5921886;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=19358282; DOI=10.1002/ijc.24351;
RA   Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M.,
RA   Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.;
RT   "Expression of the ULBP ligands for NKG2D by B-NHL cells plays an
RT   important role in determining their susceptibility to
RT   rituximab-induced ADCC.";
RL   Int. J. Cancer 125:212-221(2009).
//
RX   PubMed=24362935; DOI=10.1038/nm.3435;
RA   Rahal R., Frick M., Romero R., Korn J.M., Kridel R., Chan F.C.,
RA   Meissner B., Bhang H.-e.C., Ruddy D.A., Kauffmann A., Farsidjani A.,
RA   Derti A., Rakiec D., Naylor T., Pfister E., Kovats S., Kim S.,
RA   Dietze K., Dorken B., Steidl C., Tzankov A., Hummel M., Monahan J.E.,
RA   Morrissey M.P., Fritsch C., Sellers W.R., Cooke V.G., Gascoyne R.D.,
RA   Lenz G., Stegmeier F.;
RT   "Pharmacological and genomic profiling identifies NF-kappaB-targeted
RT   treatment strategies for mantle cell lymphoma.";
RL   Nat. Med. 20:87-92(2014).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//